Growth Hormone Secretagogue Research
Compounds studied for pituitary GH release, GH axis regulation, and body composition effects in preclinical and clinical models
Growth hormone secretagogue research examines the compounds and mechanisms that stimulate pituitary GH release, either through the GHRH receptor, the ghrelin receptor (GHS-R1a), or both simultaneously. The growth hormone axis regulates body composition, fat metabolism, lean tissue maintenance, IGF-1 production, and a range of metabolic parameters that decline with age. Compounds in this use case represent both single-receptor and dual-receptor approaches to GH secretagogue research, with different half-life profiles, feedback preservation characteristics, and clinical data profiles. Researchers designing GH axis studies select compounds based on whether they require a sustained or pulsatile stimulation pattern, and whether preserving the physiological feedback loop is important for their experimental design.
Compounds in This Use Case
Each compound contributes a distinct mechanism relevant to this research objective.
CJC-1295 / Ipamorelin
$199Role
Dual-receptor GH secretagogue blend studied for synergistic GHRH receptor and ghrelin receptor agonism, providing amplified and sustained GH pulse stimulation.
Mechanism
CJC-1295 with DAC binds albumin to extend half-life to approximately 6 to 8 days, producing sustained GHRH receptor activation. Ipamorelin selectively activates the ghrelin receptor (GHS-R1a) without significant cortisol or prolactin elevation, and the combination creates synergistic GH secretion through complementary receptor pathways.
Tesamorelin
$159Role
Full-length GHRH analog studied for physiological GH pulse stimulation with preserved somatostatin feedback, and FDA-approved for visceral fat reduction in HIV lipodystrophy.
Mechanism
Activates the GHRH receptor as a synthetic analog of full-length GHRH(1-44), stimulating pituitary GH release while preserving the somatostatin-mediated negative feedback loop, resulting in physiologically patterned GH pulses rather than sustained supraphysiological elevation.
AOD-9604
$99Role
HGH C-terminal fragment studied for adipose-specific lipolysis without GH receptor-mediated anabolic or diabetogenic effects.
Mechanism
Represents residues 176 to 191 of human growth hormone and stimulates lipolysis in adipose tissue through beta-3 adrenergic receptor interactions, without binding the GH receptor in a manner that elevates IGF-1 or promotes the anabolic effects of full HGH.
Research Context
GH secretagogue research has matured substantially with the identification of the ghrelin receptor and the development of selective GHRH analogs. Tesamorelin is the most clinically validated compound in this use case, with FDA approval and Phase 3 data for HIV lipodystrophy. CJC-1295/Ipamorelin represents a more sustained, dual-receptor approach that has been widely studied in the wellness and body composition research community. AOD-9604 offers a GH-derived approach to adipose metabolism without engaging the full GH axis, making it valuable for researchers who need to isolate the lipolytic component of GH biology from its anabolic effects.
Related Compound Comparisons
Explore side-by-side mechanism comparisons for the compounds in this use case.
Frequently Asked Questions
Source These Compounds
All compounds in this use case are available from Spartan Peptides at least 98% HPLC-verified purity. Domestic US supply with same-day dispatch before 2 PM. For in-vitro research use only.
All compounds are strictly for in-vitro research use only and not intended for human consumption.